Yasuo Seta
Overview
Explore the profile of Yasuo Seta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishida S, Takashima Y, Udagawa R, Ibaraki H, Seta Y, Ishihara H
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839933
Drug therapy for retinal diseases (e.g., age-related macular degeneration, the leading cause of blindness) is generally performed by invasive intravitreal injection because of poor drug delivery caused by the blood-retinal...
2.
Ibaraki H, Hatakeyama N, Arima N, Takeda A, Seta Y, Kanazawa T
Eur J Pharm Biopharm
. 2021 Dec;
170:170-178.
PMID: 34963657
Ulcerative colitis (UC) is a refractory inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, and significantly reduces the patient's quality of life. While existing UC treatments...
3.
Ibaraki H, Takeda A, Arima N, Hatakeyama N, Takashima Y, Seta Y, et al.
Pharmaceutics
. 2021 Jan;
13(1).
PMID: 33466905
Nanocarriers such as liposomes have been attracting attention as novel therapeutic methods for inflammatory autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. The physicochemical properties of intravenously administered nanomedicines...
4.
Ibaraki H, Kanazawa T, Owada M, Iwaya K, Takashima Y, Seta Y
Pharmaceutics
. 2020 Jan;
12(1).
PMID: 31952106
Controlling metastasis is an important strategy in cancer treatment. Nanotechnology and nucleic acids with novel modalities are promising regulators of cancer metastasis. We aimed to develop a small interfering RNA...
5.
Kanazawa T, Kurano T, Ibaraki H, Takashima Y, Suzuki T, Seta Y
Pharmaceutics
. 2019 Dec;
11(12).
PMID: 31861247
The appropriate information for the reprint used with permission from [...].
6.
Kanazawa T, Kurano T, Ibaraki H, Takashima Y, Suzuki T, Seta Y
Pharmaceutics
. 2019 Sep;
11(9).
PMID: 31540164
We previously reported that siRNA delivery to the brain is improved by the nose-to-brain delivery route and by conjugation with polyethylene glycol-polycaprolactone (PEG-PCL) polymer micelles and the cell-penetrating peptide, Tat...
7.
Ibaraki H, Kanazawa T, Kurano T, Oogi C, Takashima Y, Seta Y
Biol Pharm Bull
. 2019 Jul;
42(7):1216-1225.
PMID: 31257297
Small interfering RNA (siRNA) has been proposed as a novel treatment for atopic dermatitis (AD) because it suppresses sequence-specific mRNA expression. Indeed siRNA-based therapy achieves an almost complete cure with...
8.
Ibaraki H, Kanazawa T, Takashima Y, Okada H, Seta Y
Int J Pharm
. 2018 Mar;
542(1-2):213-220.
PMID: 29551748
Nucleic acid-based targeting of nuclear factor kappaB (NF-κB) is gaining attention as a treatment option for skin diseases like atopic dermatitis (AD). Transdermal administration improves patient quality of life because...
9.
Kanazawa T, Tamano K, Sogabe K, Endo T, Ibaraki H, Takashima Y, et al.
Biol Pharm Bull
. 2017 Nov;
40(11):1929-1933.
PMID: 29093340
Small interfering RNAs (siRNAs) are expected to offer a means of treating rheumatoid arthritis (RA) because they allow the specific silencing of genes related to RA pathogenesis. In our previous...
10.
Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, et al.
Int J Pharm
. 2017 Aug;
530(1-2):195-200.
PMID: 28757255
Recently, nose-to-brain delivery is a highly versatile route, which, in combination with novel drugs being developed for treating intractable CNS diseases, is a promising approach for the treatment of disorders....